Bottom line: I estimate Lifyorli will capture roughly 26% of US platinum-resistant ovarian cancer (PROC) treatment starts in Q4 2026. While the drug has experienced an exceptionally strong early launch, structural caps on its addressable patient population—primarily the requirement for prior bevacizumab exposure—along with natural deceleration following an initial launch bolus, will likely keep its share of new starts in the mid-20s. Furthermore, to ensure consistency with models of the drug
Set against related questions modeling the drug's long-term trajectory , this estimate was slightly smoothed to ensure consistency with later years and the overall peak share.
Launch Velocity and Baseline Denominator Lifyorli (relacorilant) received FDA approval on March 25, 2026, and achieved an exceptionally strong initial launch. Within its first roughly four months of availability, more than 1,300 patients started on therapy, generating $47.6M in revenue and rapid listing as an NCCN "preferred regimen" 44 sources. Given the baseline of approximately 20,000 US platinum-resistant ovarian cancer (PROC) treatment starts per year—roughly 5,000
Set against related forecasts, this estimate was slightly shifted to smooth the trajectory between the initial 2026 launch phase and expected steady-state by 2028 .
Baseline and Launch Trajectory Lifyorli (relacorilant) has demonstrated exceptionally strong early uptake since its March 2026 approval for platinum-resistant ovarian cancer (PROC). In its first commercial quarter (Q2 2026), it generated $47.6M and over 1,300 patient starts 2 sources. Given the estimated 20,000 US women eligible for a new PROC therapy each year (~5,000 starts per quarter) ir.corcept.com, this implies a launch-quarter share in the 15–20% range when adjusting for reve
Set against related questions, this was raised to bridge a more coherent trajectory from the 2027 estimates to the long-term peak share.
Exceptional Initial Launch Trajectory Lifyorli (relacorilant) plus nab-paclitaxel received FDA approval in March 2026 with strong Phase 3 ROSELLA data showing a 35% reduction in the risk of death (OS HR 0.65) versus chemotherapy fda.gov. Its market uptake has been rapid. By late July 2026, over 1,300 US patients had initiated therapy, generating $47.6M in its first partial quarter of availability 2 sources. NCCN added it as a preferred regimen within weeks, and >70% of combin
Set against related questions, the distribution was adjusted slightly to ensure the peak annual share sits logically above the projected quarterly shares in the early launch years .
Ask a followup
Sign in to run · $20 free credit, no card · every claim cited